Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease.

Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease.

老虎证券2026/02/12 13:08

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This key regulatory milestone paves the way for Annovis' clinical development program in the field of neurodegenerative diseases. Buntanetap, an oral small molecule drug, aims to slow the pathological progression of Alzheimer's disease by reducing levels of neurotoxic proteins. This Phase III trial will evaluate the drug's efficacy in improving cognitive function and its safety profile in patients with early-stage Alzheimer's disease. The DSMB's approval is based on a comprehensive review of Phase II clinical trial data, which showed that Buntanetap demonstrated significant efficacy on primary endpoints without major safety concerns. This decision means that the trial protocol meets ethical and scientific standards and can continue patient enrollment as planned. Annovis plans to conduct this randomized, double-blind, placebo-controlled Phase III study at multiple clinical centers worldwide, with an expected enrollment of approximately 450 patients. The company emphasized that this progress marks an important milestone for Buntanetap as a potential therapy for Alzheimer's disease.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldman Sachs believes that the rapid rise in real interest rates has exerted more direct pressure on the US stock market, with rate-sensitive sectors such as small-cap and financial stocks being particularly affected. On the liquidity front, Goldman Sachs estimates that pension funds may sell around $3.3 billions in equities at the end of the month and quarter, and that CTAs may sell about $530 million worth of Russell 2000 index futures in the coming week. For the market, unless the issues of oil and interest rates are resolved, the AI narrative is "almost irrelevant."

华尔街见闻•2026/09/30 04:01

USD/JPY falls below 157! The yen becomes the strongest G-10 currency, with the market betting on another rate hike by the central bank next month.

On Wednesday, the yen strengthened against the US dollar, with the USD/JPY rate falling below the 157 mark, as repeated warnings from the Japanese government regarding exchange rates and end-of-quarter capital flows provided support for the yen.

智通财经•2026/09/30 03:41